Sign In
Buy CLXPF
$0.82
+0 (+0%)
At Close: Aug 17, 2022
Cybin to Present at the Emerging Growth Conference on June 23rd
04:22pm, Friday, 18'th Jun 2021
TORONTO--(BUSINESS WIRE)--Cybin to Present at the Emerging Growth Conference on June 23rd
Could Cybin Be a Millionaire-Maker Stock?
11:05am, Thursday, 17'th Jun 2021
The "new" mental health therapies this Canadian biotech is developing have an unusual advantage -- there's plenty of existing research showing that they work.
Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
04:15pm, Friday, 11'th Jun 2021
TORONTO--(BUSINESS WIRE)--Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
Cybin To Co-Sponsor Clinical Trial Testing Psilocybin In Frontline Health Workers With Covid-related Distress
05:15pm, Tuesday, 08'th Jun 2021
Psychedelics and biotech company Cybin Inc. (NEO: CYBN) (OTCQB:CLXPF) is co-sponsoring a new clinical trial that will test the benefits of psilocybin treatment in health workers experiencing COVID-rel
Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021
05:59pm, Wednesday, 02'nd Jun 2021
TORONTO--(BUSINESS WIRE)--Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021
BTV Explores Investment Options in Life Sciences
06:00am, Thursday, 06'th May 2021
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - On national TV Sat. May 8 & Sun. May 9, 2021 - BTV-Business Television explores life science investment opportunities including psychedeli
Forget Sundial Growers: Put This Psychedelic Stock on Your Radar
06:05am, Thursday, 29'th Apr 2021
It's only in its early stages, but that could mean even bigger returns if the company's pipeline candidates are successful.
Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
07:15am, Wednesday, 21'st Apr 2021
TORONTO--(BUSINESS WIRE)--Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
07:15am, Tuesday, 13'th Apr 2021
TORONTO--(BUSINESS WIRE)--Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
08:30am, Friday, 26'th Mar 2021
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic Therapeuti
Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference
07:15am, Tuesday, 16'th Mar 2021
TORONTO--(BUSINESS WIRE)--Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference
Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference
07:15am, Monday, 15'th Mar 2021
TORONTO--(BUSINESS WIRE)--Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference
Cybin Inc. Releases Financial Highlights and Provides Business Update
11:22pm, Tuesday, 16'th Feb 2021
TORONTO--(BUSINESS WIRE)--Cybin Inc. Releases Financial Highlights and Provides Business Update
Cybin Included in First Psychedelic Exchange Traded Fund
02:59pm, Wednesday, 27'th Jan 2021
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it is among the select
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics Inc. (�
